Trials / Completed
CompletedNCT04736927
Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy Subjects
An Open-label, Fixed-sequence, Drug-drug Interaction Study in Healthy Subjects to Evaluate the Effect of GLPG3667 on the Pharmacokinetics of Midazolam, a Sensitive Index Substrate of CYP3A4
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A study in healthy volunteers to look at the effect of the test medicine, GLPG3667, on how midazolam (MDZ) is taken up and eliminated by the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLPG3667 | From Day 3 to Day 8, GLPG3667 capsules q.d. orally in fed state. |
| DRUG | Midazolam | On Day 1 and Day 7 as liquid formulation, orally in fed state. |
Timeline
- Start date
- 2021-01-15
- Primary completion
- 2021-02-25
- Completion
- 2021-02-25
- First posted
- 2021-02-03
- Last updated
- 2021-03-03
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04736927. Inclusion in this directory is not an endorsement.